EP3723743A4 - Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique - Google Patents
Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique Download PDFInfo
- Publication number
- EP3723743A4 EP3723743A4 EP18915505.4A EP18915505A EP3723743A4 EP 3723743 A4 EP3723743 A4 EP 3723743A4 EP 18915505 A EP18915505 A EP 18915505A EP 3723743 A4 EP3723743 A4 EP 3723743A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- dapoxetine
- inhibitor
- pharmaceutical combination
- phosphodiesterase type
- emetic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title 1
- 239000002111 antiemetic agent Substances 0.000 title 1
- 229940125683 antiemetic agent Drugs 0.000 title 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 title 1
- 229960005217 dapoxetine Drugs 0.000 title 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR201720443 | 2017-12-15 | ||
PCT/TR2018/050806 WO2019203753A2 (fr) | 2017-12-15 | 2018-12-13 | Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3723743A2 EP3723743A2 (fr) | 2020-10-21 |
EP3723743A4 true EP3723743A4 (fr) | 2021-09-08 |
Family
ID=68240624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18915505.4A Withdrawn EP3723743A4 (fr) | 2017-12-15 | 2018-12-13 | Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3723743A4 (fr) |
WO (1) | WO2019203753A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023179542A1 (fr) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | Dérivés de 5,8-dihydro-1,7-naphtyridine utiles en tant qu'agonistes de glp-1 pour le traitement du diabète |
WO2023198140A1 (fr) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques de glp-1 |
WO2024125602A1 (fr) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Sels et formes solides d'un composé ayant une activité agoniste de glp-1 |
WO2024138048A1 (fr) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Agonistes de glp-1 hétérocycliques |
WO2024131869A1 (fr) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Agonistes hétérocycliques du glp-1 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020037828A1 (en) * | 1997-10-28 | 2002-03-28 | Wilson Leland F. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US20150202168A1 (en) * | 2012-08-17 | 2015-07-23 | Sanovel llac Sanayi Ve Ticaret Anonim Sirketi | Oral film formulations comprising dapoxetine and tadalafil |
-
2018
- 2018-12-13 WO PCT/TR2018/050806 patent/WO2019203753A2/fr unknown
- 2018-12-13 EP EP18915505.4A patent/EP3723743A4/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020037828A1 (en) * | 1997-10-28 | 2002-03-28 | Wilson Leland F. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US20150202168A1 (en) * | 2012-08-17 | 2015-07-23 | Sanovel llac Sanayi Ve Ticaret Anonim Sirketi | Oral film formulations comprising dapoxetine and tadalafil |
Also Published As
Publication number | Publication date |
---|---|
WO2019203753A2 (fr) | 2019-10-24 |
WO2019203753A3 (fr) | 2020-01-16 |
EP3723743A2 (fr) | 2020-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3805264A4 (fr) | Anticorps anti-interleukine 17a, composition pharmaceutique et utilisation associées | |
EP3723743A4 (fr) | Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique | |
EP3741374A4 (fr) | Inhibiteur de mtor, composition pharmaceutique et son utilisation | |
EP3749317A4 (fr) | Pémétrexed alpha-polyglutamaté et utilisations associées | |
EP3463253A4 (fr) | Dispositifs, systèmes et/ou procédés de distribution de pilules | |
EP3782998A4 (fr) | Composé de pyrrolotriazine substitué, composition pharmaceutique et utilisation associées | |
EP3965772A4 (fr) | Composition pharmaceutique à base de brexanolone, de ganaxolone ou de zuranolone, et son utilisation | |
EP3680331A4 (fr) | Protéine cas9 modifiée et utilisation de celle-ci | |
EP3802562A4 (fr) | Nouvelle utilisation pharmaceutique | |
EP3421038A4 (fr) | Composé de naphtyridine, composition pharmaceutique et leur utilisation | |
EP4061941A4 (fr) | Rétrotransposons et leur utilisation | |
SG11201908281VA (en) | Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof | |
EP3685828A4 (fr) | Composition pharmaceutique ophtalmique, trousse ophtalmique et application pharmaceutique associée | |
EP3810143A4 (fr) | Inhibiteurs de la nadph oxydase, composition pharmaceutique les comprenant et application de ceux-ci | |
EP3731837A4 (fr) | Combinaison contenant de la linagliptine et de la metformine | |
EP3580288A4 (fr) | Composition de revêtement, procédé pour sa préparation et utilisation correspondante | |
EP3770148A4 (fr) | Inhibiteur de récepteur, composition pharmaceutique le comprenant et son utilisation | |
GB2606804B (en) | Benzenesulfonamide derivatives and uses thereof | |
EP3856242A4 (fr) | Anticorps anti-siglec, composition pharmaceutique le comprenant, et leurs utilisations | |
SG11202101435XA (en) | ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
EP3904429A4 (fr) | Poudre de cellulose, son utilisation et comprimé | |
EP3719010A4 (fr) | Composé aromatique, composition pharmaceutique et utilisation associées | |
EP3694519A4 (fr) | Combinaison pharmaceutique comprenant de la dapoxétine et de la phosphodiestérase de type 5 | |
EP3999056A4 (fr) | Combinaison pharmaceutique et son utilisation | |
WO2017173302A3 (fr) | Inhibiteurs de l'intégrine alpha 5 bêta 1 et leurs procédés d'utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200323 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TUERKYILMAZ, ALI. Inventor name: PALATOEKEN, ARZU. Inventor name: GUENER, DICLE. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210811 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/166 20060101ALI20210805BHEP Ipc: A61K 31/519 20060101ALI20210805BHEP Ipc: A61K 31/4985 20060101ALI20210805BHEP Ipc: A61K 9/20 20060101ALI20210805BHEP Ipc: A61K 31/138 20060101AFI20210805BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20220311 |